ATBECHDEDKESFRGBGRITLILUNLSE..PTIE..................................................................
J
DIM360 Ver 2.15 (14 Jul 2008) - 2720000/0
de
Teilanmeldung 96101147.5 eingereicht am 26/01/96.
en
Divisional application 96101147.5 filed on 26/01/96.
fr
Demande divisionnaire 96101147.5 déposée le 26/01/96.
The file contains technical information submitted after the application was filed and not included in this specification
0699436
NEW EUROPEAN PATENT SPECIFICATION
After opposition procedure
B2
20130320
EP
95114527.5
19940429
19951003
19970609
20130320
en
en
en
4315525
19930510
DE
9324045
19931123
GB
9404544
19940309
GB
9404928
19940314
GB
20130320
201312
19960306
199610
20010613
200124
20000428
20001106
20130320
201312
A61K 31/135 20060101AFI19951111BHEP
A61K 9/16 20060101ALI19951111BHEP
A61K 9/20 20060101ALI19951111BHEP
de
Arzneimittel mit kontrollierter Wirkstoffabgabe
en
Controlled release formulation
fr
Composition à libération contrôlée
EP-A- 0 147 780
US-A- 5 073 379
CHEMICAL ABSTRACTS, vol. 112, no. 10, 5 March 1990, Columbus, Ohio, US; abstract no. 84206, & JP-A-01 149 717 (SHOWA DENKO K.K.) 12 June 1989
LINTZ ET AL.: 'Bioavailability of Enteral Tramadol Formulations' ARZNEIM.-FORSCH./DRUG RES. vol. 36 (II), no. 8, 1986,
94303128.6
0624366
19940429
96101147.5
0729751
19960126
04014719.1
1468679
20040623
04030658.1
1527775
20041223
09004973.5
2103303
20090403
Miller, Ronald Brown
Schutzenmattstrasse
CH-4051 Basel
CH
Leslie, Stewart Thomas
4 Babraham Road
Cambridge
GB
Malkowska, Sandra Therese Antoinette
21 Broadway, Wilburton
Ely, Cambridgeshire
GB
Smith, Kevin John
18 Poplar Road
Histon, Cambridge
GB
Wimmer, Walter
Blumenroder Strasse 88
D-65549 Limburg
DE
Winkler, Horst
Mainzer Strasse 15
D-65550 Linter
DE
Hahn, Udo
Nordstrasse 1
D-56412 Nentershausen
DE
Prater, Derek Allan
28 Pearson Close
Milton, Cambridge
GB
EURO-CELTIQUE S.A.
101031225
E 7799/WM
2, avenue Charles de Gaulle
1653 Luxembourg
LU
Maiwald Patentanwalts GmbH
100061181
Elisenhof Elisenstrasse 3
80335 München
DE
01
20020312
1
SMB S.A.
100705062
Rue de la Pastorale 26-28
1080 Bruxelles
BE
ter Meer, Nicolaus
et al
101270906
ter Meer Steinmeister & Partner GbR Mauerkircherstrasse 45
81679 München
DE
02
20020312
4
Lannacher Heilmittel Ges.m.b.H.
100703161
Schlossplatz 1
8502 LANNACH
AT
Muth, Heinz-Peter
et al
100040828
Uexküll & Stolberg Patentanwälte Beselerstrasse 4
22607 Hamburg
DE
03
20020313
1
Hexal Aktiengesellschaft
100702345
Industriestr. 25
83607 Holzkirchen
DE
Wibbelmann, Jobst
et al
100034117
Wuesthoff & Wuesthoff Patent- und Rechtsanwälte Schweigerstrasse 2
81541 München
DE
04
20020313
1
Zentiva k.s.
101091277
U kabelovny 130
10237 Praha 10
CZ
Teipel, Stephan
et al
101112612
Lederer & Keller Patentanwälte Unsöldstrasse 2
80538 München
DE
AT
BE
CH
DE
DK
ES
FR
GB
GR
IE
IT
LI
LU
NL
PT
SE
19960306
199610
The present invention relates to a controlled release preparation for oral administration, to processes for its preparation and to its medical use. In particular, the invention relates to a controlled release preparation comprising tramadol or a pharmaceutically acceptable salt thereof.
Tramadol, which has the chemical name (±)-trans-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol, is an orally active opioid analgesic. Conventional release preparations in the form of capsules, drops and suppositories containing tramadol, or more particularly its hydrochloride salt, have been commercially available for many years for use in the treatment of moderate to severe pain; such preparations, however, do not provide a controlled release of the tramadol. Moreover, despite tramadol's long-standing use, controlled release preparations for oral administration containing tramadol as active ingredient have not even previously been described in the literature.
EP 147,780 relates to a drug delivery and mentions tramadol.
It is an object of the present invention to provide an oral controlled release tramadol preparation suitable for twenty-four hourly administration for the treatment of pain.
The present invention therefore provides a controlled release preparation comprising tramadol hydrochloride (HCl) for oral administration.
A controlled release preparation according to the present invention is one that achieves slow release of tramadol HCl over an extended period of time, thereby extending the duration of drug action over that achieved by conventional delivery. Such a preparation maintains a drug concentration in the blood within the therapeutic range for 24 hours.
Thus, in accordance with the invention, there is provided an oral controlled release preparation of tramadol HCl effective for the treatment of moderate to severe pain for 24 hours, wherein:
- the oral controlled release preparation comprises the tramadol HCl in a controlled release matrix in the form of multiparticulates, the matrix consisting of tramadol HCl and hydrogenated vegetable oil having a melting point of 35 to 140°C, wherein said multiparticulates are admixed with tabletting excipients and compressed into a tablet and wherein the controlled release preparation provides an in vitro release rate of claim 1.
The present inventors have found that for once-a-day dosing, the in vitro release rate corresponds to the following % rate of tramadol released:

TABLE 1
TIME (H) | % TRAMADOL RELEASED
1 | 10-30
2 | 17-37
4 | 27-47
8 | 40-60
12 | 49-69
16 | 57-77
A formulation in accordance with the invention suitable for once-a-day dosing may have a tmax in the range of 3 to 6 hours, preferably 4 to 5 hours and a W_{50} value in the range of 10 to 33 hours.
The W_{50} parameter defines the width of the plasma profile at 50% Cmax, i.e. the duration over which the plasma concentrations are equal to or greater than 50% of the peak concentration. The parameter is determined by linear interpolation of the observed data and represents the difference in time between the first (or only) upslope crossing and the last (or only) downslope crossing in the plasma profile.
The in vitro release rates mentioned herein are, except where otherwise specified, those obtained by measurement using the Ph. Eur. Paddle Method at 100rpm in 900ml 0.1 N hydrochloric acid at 37°C and using UV detection at 270nm.
The controlled release preparation according to the invention preferably contains an analgesically effective amount of tramadol HCl, conveniently in the range of from 50 to 400 mg, especially 100, 200, 300 or 400 mg tramadol hydrochloride per dosage unit.
The controlled release preparation according to the invention is presented as tablets.
The active ingredient in the preparation according to the invention will be incorporated in a controlled release matrix as defined in claim 1. This matrix affords controlled release tramadol over a 24 hour period and affords in-vitro dissolution rates and in vivo absorption rates of tramadol within the ranges specified above.
Materials for inclusion in a controlled release matrix are hydrogenated vegetable oils having a melting point of 35 to 140°C.
One preferred form of unit dose form in accordance with the invention comprises a tablet made from controlled release particles in the form of matrix multiparticulates consisting of the active ingredient and hydrogenated vegetable oil having a melting point of 35 to 140°C. In particular, the controlled release particles are preferably prepared by a process which comprises forming a mixture of dry active ingredient and hydrogenated vegetable oil having a melting point of 35 to 140°C followed by mechanically working the mixture in a high speed mixer with an energy input sufficient to melt or soften hydrogenated vegetable oil having a melting point of 35 to 140°C whereby it forms particles with the active ingredient. The resultant particles, after cooling, are suitably sieved to give particles having a size range from 0.1 to 3.0mm, preferably 0.25 to 2.0mm. An example according to the invention is described below which is suitable for the commercial production of dosage units.
When using such a processing technique it has been found that, in order most readily to achieve the desired release characteristics (both in vivo and in vitro as discussed above) the composition to be processed consists of two essential ingredients namely:
- (a) tramadol HCl; and
- (b) hydrogenated vegetable oil having a melting point of 35 to 140°C
We have found that the total amount of tramadol HCl in the composition may vary within wide limits, for example from 10 to 90% by weight thereof.
Another preferred process for the manufacture of a formulation in accordance with the invention comprises
- (a) mechanically working in a high-speed mixer, a mixture of tramadol HCl in particulate form and a particulate, hydrogenated vegetable oil having a melting point of 35 to 140°C at a speed and energy input which allows the hydrogenated vegetable oil having a melting point of 35 to 140°C to melt or soften, whereby it forms agglomerates,
- (b) breaking down the larger agglomerates to give controlled release seeds; and
- (c) continuing mechanically working with optionally a further addition of low percentage of the hydrogenated vegetable oil having a melting point of 35 to 140°C .
- (d) optionally repeating steps (c) and possibly (b) one or more times.
This process is capable of giving a high yield (over 80%) of particles in a desired size range, with a desired uniformity of release rate of tramadol or salt thereof.
The resulting particles may be sieved to eliminate any over-or undersized material then formed into tablets by compression.
In this method in accordance with the invention preferaby all the tramadol HCl is added in step (a) together with a major portion of the hydrogenated vegetable oil having a melting point of 35 to 140°C. Preferably the amount of hydrogenated vegetable oil having a melting point of 35 to 140°C added in step (a) is between 10% and 90% w/w of the total amount of ingredients added in the entire manufacturing operation, more preferably between 20% and 70% w/w.
Stage (a) of the process may be carried out in conventional high speed mixers with a standard stainless steel interior, e.g. a Collette Vactron 75 or equivalent mixer. The mixture is processed until a bed temperature about 40°C or above is achieved and the resulting mixture acquires a cohesive granular texture, with particle sizes ranging from about 1-3mm to fine powder in the case of non-aggregated original material. Such material, in the case of the embodiments described below, has the appearance of agglomerates which upon cooling below 40°C have structural integrity and resistance to crushing between the fingers. At this stage the agglomerates are of an irregular size, shape and appearance.
The agglomerates are preferably allowed to cool. The temperature to which it cools is not critical and a temperature in the range room temperature to 37°C may be conveniently used.
The agglomerates are broken down by any suitable means, which will comminute oversize agglomerates and produce a mixture of powder and small particles preferably with a diameter under 2mm. It is currently preferred to carry out the classification using a Jackson Crockatt granulator using a suitable sized mesh, or a Comil with an appropriate sized screen. We have found that if too small a mesh size is used in the aforementioned apparatus the agglomerates melting under the action of the beater or impeller will clog the mesh and prevent further throughput of mixture, thus reducing yield. A mesh size of 12 has been found adequate.
The classified material is returned to the high speed mixer and processing continued. It is believed that this leads to cementation of the finer particles into particles of uniform size range.
In one preferred form of the method of the invention processing of the classified materials is continued, until the hydrogenated vegetable oil having a melting point of 35 to 140°C used begin to soften/melt and optionally additional hydrogenated vegetable oil having a melting point of 35 to 140°C is then added. Mixing is continued until the mixture has been transformed into particles of the desired predetermined size range.
In order to ensure uniform energy input into the ingredients in the high speed mixer it is preferred to supply at least part of the energy by means of microwave energy.
Energy may also be delivered through other means such as by a heating jacket or via the mixer impeller and chopper blades.
After the particles have been formed they are cooled or allowed to cool, and may then be sieved to remove any over or undersized material.
The resulting particles may be used to prepare dosage units in accordance with the invention in the form of tablets in manners known per se.
We have also found that particles containing tramadol HCl produced by a melt processing as described in application PCT/SE93/00225 and the process described and claimed in our prior unpublished UK application No. 9324045.5 filed on 23 November 1993 as well as the process described herein are particularly useful for processing into the form of tablets.
We have found that by suitable selection of the materials used in forming the particles and in the tabletting and the proportions in which they are used, enables a significant degree of control in the ultimate dissolution and release rates of the tramadol or salt thereof from the compressed tablets.
To form a tablet in accordance with the invention, particles prepared as described above will be admixed with tabletting excipients e.g. one or more of the standard excipients' such as diluents, lubricants, binding agents, flow aids, disintegrating agents, surface active agents or water soluble polymeric materials.
Suitable diluents are e.g. microcrystalline cellulose, lactose and dicalcium phosphate. Suitable lubricants are e.g. magnesium stearate and sodium stearyl fumarate.
Suitable binding agents are e.g. hydroxypropyl methyl cellulose, polyvidone and methyl cellulose.
Suitable disintegrating agents are starch, sodium starch glycolate, crospovidone and croscarmalose sodium.
Suitable surface active are Poloxamer 188® , polysorbate 80 and sodium lauryl sulfate. Suitable flow aids are talc colloidal anhydrous silica.
Suitable water soluble polymers are PEG with molecular weights in the range 1000 to 6000.
To produce tablets in accordance with the invention, particles produced in accordance with the invention may be mixed or blended with the desired excipient(s), if any, using conventional procedures, e.g. using a Y-Cone or bin-blender and the resulting mixture compressed according to conventional tabletting procedure using a suitable size tabletting mould. Tablets can be produced using conventional tabletting machines, and in the embodiments described below were produced on standard single punch F3 Manesty machine or Kilian RLE15 rotary tablet machine.
Generally speaking we find that even with such a highly water soluble active agent as tramadol HCl tablets formed by compression according to standard methods give very low release rates of the active ingredient e.g. corresponding to release over a period of greater than 24 hours, say more than 36. We have found that the release profile can be adjusted in a number of ways. For instance a higher loading of the drug will be associated with increased release rates; the use of surface active agent in the tabletting formulation will also be associated with a higher release rate of the active ingredient. By controlling the relative amounts of these ingredients it is possible to adjust the release profile of the tramadol or salt thereof.
In order that the invention may be well understood the following examples are given by way of illustration only. Examples 1 to 3 are Examples and relate to preparations in accordance with EP 1468679B1. These examples are not covered by the claims.

Example 1
Tablets having the following formulation were prepared:
| mg/tablet
Tramadol Hydrochloride | 100
Lactose Ph. Eur. | 68.0
Ethylcellulose (Surelease® 25% solids) | 15
Purified Water Ph. Eur. | 13.3∗
Cetostearyl Alcohol Ph. Eur. (Dehydag wax 0) | 42.00
Magnesium Stearate Ph. Eur. | 2.00
Purified Talc Ph. Eur. | 3.00
| 230.00
∗ Removed during processing.
Tramadol hydrochloride (100mg) and lactose (68mg) were granulated, transferred to a fluid bed granulator and sprayed with ethylcellulose (15mg) and water. The granules were then dried at 60°C and passed through a lmm screen.
To the warmed tramadol containing granules was added molten cetostearyl alcohol (42mg) and the whole was mixed thoroughly. The granules were allowed to cool and sieved through a 1.6mm screen. Purified talc and magnesium stearate were added and mixed with the granules. The granules were then compressed into tablets.
The tablets were coated with a film coat having the formulation given below.
| mg/tablet
Hydropropylmethylcellulose Ph. Eur. 15 cps (Methocel E15) | 0.770
Hydroxypropylmethylcellulose (Ph. Eur. 5 cps (Methocel E5) | 3.87
Opaspray M-1-7111B (33% solids) | 2.57
Polyethylene glycol 400 USNF | 0.520
Purified Talc Ph. Eur. | 0.270
Purified Water Ph. Eur. | 55.52 ∗
∗ Remove during processing.

Example 2
Tablets having the following formulation were prepared:
| mg/tablet
Tramadol hydrochloride | 100.0
Lactose Ph. Eur. | 58.0
Ethylcellulose USNF (Ethocel 45 CP) | 15.0
Cetostearyl alcohol Ph. Eur. (Dehydag wax O) | 52.0
Magnesium stearate Ph. Eur. | 2.00
Purified talc Ph. Eur. | 3.00
A mixture of tramadol hydrochloride (100mg), lactose (58mg) and ethylcellulose (15mg) was granulated whilst adding molten cetostearyl alcohol (52mg) and the whole was mixed thoroughly. The granules were allowed to cool and sieved through a 1.6mm screen. Purified talc and magnesium stearate were added and mixed with the granules. The granules were then compressed into tablets which were coated with a film coat having the formulation given in Example 1.

Example 3
Film coated tablets were produced following the procedure described in Example 2 and having the following formulation:
| mg/tablet
Tramadol hydrochloride | 100.00
Lactose Ph. Eur. | 70.50
Hydroxyethylcellulose Ph. Eur. | 12.50
Cetostearyl alcohol Ph. Eur. | 42.00
Magnesium stearate Ph. Eur. | 2.00
Purified talc Ph. Eur. | 3.00

In vitro dissolution studies
In vitro dissolution studies were conducted on tablets prepared as described above. Results are given in Table 1.

TABLE 1
WT % TRAMADOL RELEASED
Time (h) | Example 1 | Example 2∗ | Example 3
1 | 39 | 35 | 43
2 | 52 | 47 | 60
4 | 67 | 62 | 84
8 | 82 | 78 | 97
12 | 90 | 86 | -
∗ Measured on tablet core
In a trial involving 12 healthy volunteers the serum levels of tramadol following administration of one tablet according to Example 2 was found to be as illustrated in Figure 1.

Example 4 and 5
Particles having the formulations given in Table II below , were prepared by the steps of:
i. Placing the ingredients (a) and (c) (total batch weight 0.7kg) in the bowl of a 10 litre capacity Collette Gral Mixer (or equivalent) equipped with variable speed mixing and granulating blades;
ii. Mixing the ingredients at about 150-1000rpm whilst applying heat until the contents of the bowl are agglomerated.
iii. Classifying the agglomerated material by passage through a Comil and/or Jackson Crockatt to obtain controlled release seeds.
iv. Warming and mixing the classified material in the bowl of a 10 litre Collette Gral, until uniform multiparticulates of the desired pre-determined size range are formed in yield of greater than 80%. This takes approximately 5 minutes.
v. Discharging the multiparticulates from the mixer and sieving them to separate out the multiparticulates collected between 0.5 and 2mm aperture sieves.

TABLE II
Example | 4 | 5
(a) Tramadol HCl (Wt%) | 50 | 75
(b) Hydrogenated Vegetable Oil (Wt%) | 50 | 25

Example 6
Samples of the particles from Example 4 were blended with magnesium stearate and purified talc using a Y-Cone or bin-blender. The blended mixture was then compressed using either (1) 14 x 6mm, (2) 16 x 7mm or (3) 18.6 x 7.5mm capsule shaped tooling on a single punch F3 Manesty tabletting machine to give tablets giving 200, 300 and 400mg of tramadol HCl. The ingredients per dosage unit amounted to the following:
TABLE III
TABLET | MG/TABLET
INGREDIENT | 1 | 2 | 3
Tramadol Hcl | 200 | 300 | 400
Hydrogenated Vegetable Oil | 200 | 300 | 400
Sub Total | 400 | 600 | 800
Purified Talc | 12.63 | 18.95 | 25.26
Magnesium Stearate | 8.42 | 12.63 | 16.84
The tablets were assessed by the dissolution using Ph. Eur. Paddle Method 100 rpm, 0.1 N HCl.
To assess the non-compressed particles the Ph Eur. Paddle was replaced by a modified Ph Eur. Basket.
The results are shown in Table IV below;

TABLE IV
HOURS AFTER START OF TEST | Particles | Tablet 1 | Tablet 2 | Tablet 3
| % TRAMADOL HCl RELEASED
1 | 54 | 16 | 15 | 15
2 | 68 | 23 | 20 | 21
3 | 76 | 28 | 25 | 25
4 | 82 | 32 | 28 | 28
6 | 89 | 40 | 35 | 35
8 | 93 | 46 | 41 | 40
10 | 96 | 50 | 45 | 45
12 | 98 | 55 | 49 | 49
16 | 100 | 63 | 57 | 56
20 | NR | 70 | 63 | NR
These results confirm the effectiveness of the tabletting in reducing the release rate.

Example 7
Samples of the particles from Example 5 were then tabletted using a procedure similar to Example 3 and the ingredients per unit dosage amounted to:
TABLE V
TABLET | MG/TABLET
INGREDIENT | 4 | 5 | 6
Tramadol Hcl | 200 | 300 | 400
Hydrogenated Vegetable Oil | 66.7 | 100 | 133
Sub Total | 266.7 | 400 | 533
Purified Talc | 7.63 | 11.44 | 15.25
Magnesium Stearate | 5.16 | 7.63 | 10.17
The tablets and samples of non-compressed multiparticulates (each sample containing 400mg of tramadol hydrochloride) were assessed by the dissolution method also described above. The results are shown in Table VI below;

TABLE VI
HOURS AFTER START OF TEST | Particles | Tablet 4 | Tablet 5 | Tablet 6
| % TRAMADOL HCl RELEASED
1 | 77 | 43 | 40 | 42
2 | 92 | 64 | 55 | 56
3 | 98 | 75 | 65 | 66
4 | 100 | 83 | 72 | 73
6 | 102 | 94 | 83 | 84
8 | 102 | 100 | 91 | 91
10 | 102 | NR | 96 | 97
These results show that by increasing the loading of the highly water soluble tramadol hydrochloride (75% w/w in this example compared with 50% w/w in Example 6) a significantly faster release rate of the active ingredient can be achieved.

Example 8
Example 4 was repeated but with the following formulation:
Tramadol HCl | 200 mg/tablet
Hydrogenated Vegetable Oil | 163.0 mg/tablet
The resulting multiparticulates were blended as described in Example 6 with the following;
Purified Talc | 11.5 mg/tablet
Magnesium Stearate | 7.66 mg/tablet
The blend was then compressed as described in Example 6 but using 15mm x 6.5mm normal concave capsule shaped plain/plain punches.
The resulting tablets were then assessed by the dissolution method described above. The results are shown in Table V.
HOURS AFTER START OF TEST | % TRAMADOL HCl RELEASED
1 | 20
2 | 27
3 | 32
4 | 37
6 | 44
8 | 50
10 | 55
12 | 60
16 | 67
20 | 73
24 | 77
In a trial involving five healthy male volunteers the plasma profile resulting from single dose administrations of the above tablet are shown in Figure 2 in comparison to the administration of a commercial preparation of Tramadol drops 100mg.
1. An oral controlled release preparation of tramadol hydrochloride, effective for the treatment of moderate to severe pain for 24 hours, wherein:
the oral controlled release preparation comprises tramadol hydrochloride in a controlled release matrix in the form of multiparticulates, the matrix consisting of tramadol hydrochloride and hydrogenated vegetable oil having a melting point of 35 to 140 C, wherein said multiparticulates are admixed with tabletting excipients and compressed into a tablet;
and wherein the in vitro release rate of tramadol hydrochloride when measured using the Ph. Eur. Paddle Method at 100 rpm in 900 ml 0.1 N hydrochloric acid at 37°C and using UV detection at 270 nm, is:
time (h) | % released
1 | 10-30
2 | 17-37
4 | 27-47
8 | 40-60
12 | 49-69
16 | 57-77
1. Eine orale kontrolliert-freisetzende Zusammensetzung von Tramadol-Hydrochlorid, wirksam zur Behandlung von mäßigen bis starken Schmerzen für 24 Stunden, wobei:
die oral kontrolliert-freisetzende Zusammensetzung Tramadol-Hydrochlorid in einer kontrolliert-freisetzenden Matrix in der Form von mehrteiligen Feststoffteilchen umfasst, die Matrix bestehend aus Tramadol-Hydrochlorid und hydriertem Pflanzenöl mit einem Schmelzpunkt von 35 bis 140 °C,
wobei besagte mehrteilige Feststoffteilchen mit Tablettenbestandteilen vermischt und in eine Tablette verpresst werden;
und wobei die in vitro Freisetzungsrate von Tramadol-Hydrochlorid,
gemessen unter Anwendung der Paddelmethode gemäß Eur. Ph. bei 100 U/min in 900 ml 0,1 N Salzsäure bei 37°C und mit UV-Nachweis bei 270 nm, wie folgt verläuft:
Zeit (h) | Freisetzung in %
1 | 10-30
2 | 17-37
4 | 27-47
8 | 40-60
12 | 49-69
16 | 57-77
1. Préparation orale à libération contrôlée de chlorhydrate de tramadol efficace pour le traitement d'une douleur modérée à sévère pendant 24 heures, dans laquelle:
la préparation orale à libération contrôlée comprend le chlorhydrate de tramadol dans une matrice à libération contrôlée et sous la forme de matières multi-particulaires, la matrice comportant le chlorhydrate de tramadol et une huile végétale hydrogénée ayant un point de fusion de 35 à 140°C, dans laquelle lesdites matières multi-particulaires sont mélangées à des excipients pour l'élaboration de comprimés, puis comprimées en vue d'obtenir un comprimé ;
et dans laquelle la vitesse de libération in vitro de chlorhydrate de tramadol, lorsqu'elle est mesurée en appliquant la méthode Ph. Eur. Paddle à 100 tours/minute, dans 900 ml d'acide chlorhydrique 0,1 N à 37°C et en utilisant une détection aux UV à 270 nm, est comme suit:
TEMPS (h) | LIBERATION (%)
1 | 10-30
2 | 17-37
4 | 27-47
8 | 40-60
12 | 49-69
16 | 57-77

REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description
- EP
147780
A
[0003]
- SE
9300225
W
[0032]
- GB
9324045
A
19931123
[0032]
- EP
1468679
B1
[0039]